BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol Med 2021;27:482-500. [PMID: 33500194 DOI: 10.1016/j.molmed.2020.12.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 35.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Fan Z, Meng Y, Liu S, Zhan H. Blood-based DNA methylation signatures in cancer: A systematic review. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2023;1869:166583. [DOI: 10.1016/j.bbadis.2022.166583] [Reference Citation Analysis]
2 He Y, Guo W, Xu M, Huang J, Zhang X, Su H, Hong D, Liu Q. Concordance of Genomic Profiles in Matched Tissue and Plasma Samples From Chinese Patients With Lung Cancer. Clin Med Insights Oncol 2022;16:11795549221116834. [PMID: 36310733 DOI: 10.1177/11795549221116834] [Reference Citation Analysis]
3 Buzova D, Braghini MR, Bianco SD, Lo Re O, Raffaele M, Frohlich J, Kisheva A, Crudele A, Mosca A, Sartorelli MR, Balsano C, Cerveny J, Mazza T, Alisi A, Vinciguerra M. Profiling of cell-free DNA methylation and histone signatures in pediatric NAFLD: A pilot study. Hepatol Commun 2022. [PMID: 36264206 DOI: 10.1002/hep4.2082] [Reference Citation Analysis]
4 Zhang C, Zhou W, Tan Y, Tian D, Zhong C. 5-Hydroxymethylcytosines in circulating cell-free DNA reveal a diagnostic biomarker for glioma. Heliyon 2022;8:e11022. [PMID: 36281400 DOI: 10.1016/j.heliyon.2022.e11022] [Reference Citation Analysis]
5 Zheng J, Wang Y, Hu C, Zhu M, Ii J, Lin C, Lu C, Dou Y, Zhao C, Zhang Y, Wu D, Li L, Tang H, He T, Pan C, Han R, He Y. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer. Thorac Cancer 2022. [PMID: 36193794 DOI: 10.1111/1759-7714.14668] [Reference Citation Analysis]
6 Komarnicki P, Musiałkiewicz J, Stańska A, Maciejewski A, Gut P, Mastorakos G, Ruchała M. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. JCM 2022;11:5542. [DOI: 10.3390/jcm11195542] [Reference Citation Analysis]
7 Acar HZ, Özer N. The implication of molecular markers in the early stage diagnosis of colorectal cancers and precancerous lesions. Turkish Journal of Biochemistry 2022;0. [DOI: 10.1515/tjb-2022-0052] [Reference Citation Analysis]
8 Yao X, Zhou Z, Xie Y, Huang Z, Lu S, Liu C, Wang J, Li X. Methodology established for the detection of circulating tumor DNA by hybridization capture. Biotechniques 2022. [PMID: 36065956 DOI: 10.2144/btn-2022-0029] [Reference Citation Analysis]
9 Jang A, Rauterkus GP, Vaishampayan UN, Barata PC. Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer. Onco Targets Ther 2022;15:897-912. [PMID: 36051571 DOI: 10.2147/OTT.S285758] [Reference Citation Analysis]
10 Hai L, Li L, Liu Z, Tong Z, Sun Y. Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer. MedComm (2020) 2022;3:e134. [PMID: 35756163 DOI: 10.1002/mco2.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ji F, Chen L, Chen Z, Luo B, Wang Y, Lan X. TCR repertoire and transcriptional signatures of circulating tumour-associated T cells facilitate effective non-invasive cancer detection. Clin Transl Med 2022;12:e853. [PMID: 36134717 DOI: 10.1002/ctm2.853] [Reference Citation Analysis]
12 Li D, Zhang L, Fu J, Huang H, Liu Y, Zhu L, Sun H, Sun S, Zhang D, Tian T, Wang F, Hu F, Peng X, Li G, Zhao L, Zheng T, Wang X, Cui B, Zhao Y. Discovery and validation of tissue-specific DNA methylation as noninvasive diagnostic markers for colorectal cancer. Clin Epigenetics 2022;14:102. [PMID: 35974349 DOI: 10.1186/s13148-022-01312-9] [Reference Citation Analysis]
13 Pereira de Souza NM, Machado BH, Padoin LV, Prá D, Fay AP, Corbellini VA, Rieger A. Rapid and low-cost liquid biopsy with ATR-FTIR spectroscopy to discriminate the molecular subtypes of breast cancer. Talanta 2022. [DOI: 10.1016/j.talanta.2022.123858] [Reference Citation Analysis]
14 Sánchez-herrero E, Serna-blasco R, Robado de Lope L, González-rumayor V, Romero A, Provencio M. Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Front Oncol 2022;12:943253. [DOI: 10.3389/fonc.2022.943253] [Reference Citation Analysis]
15 Shen Y, Lian D, Shi K, Gao Y, Hu X, Yu K, Zhao Q, Feng C. Cancer Risk and Mutational Patterns Following Organ Transplantation. Front Cell Dev Biol 2022;10:956334. [DOI: 10.3389/fcell.2022.956334] [Reference Citation Analysis]
16 Lau BT, Almeda A, Schauer M, Mcnamara M, Bai X, Meng Q, Partha M, Grimes SM, Lee H, Heestand GM, Ji HP. Single molecule methylation profiles of cell-free DNA in cancer with nanopore sequencing.. [DOI: 10.1101/2022.06.22.497080] [Reference Citation Analysis]
17 Temraz S, Nasr R, Mukherji D, Kreidieh F, Shamseddine A. Liquid Biopsy Derived Circulating Tumor Cells and Circulating Tumor DNA as Novel Biomarkers in Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35758097 DOI: 10.1080/14737159.2022.2094706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Taklifi P, Palizban F, Mehrmohamadi M. Integrating chromatin accessibility states in the design of targeted sequencing panels for liquid biopsy. Sci Rep 2022;12:10447. [PMID: 35729208 DOI: 10.1038/s41598-022-14675-z] [Reference Citation Analysis]
19 Guemri J, Pierre-Jean M, Brohard S, Oussada N, Horgues C, Bonnet E, Mauger F, Deleuze JF. Methylated ccfDNA from plasma biomarkers of Alzheimer's disease using targeted bisulfite sequencing. Epigenomics 2022. [PMID: 35416052 DOI: 10.2217/epi-2021-0491] [Reference Citation Analysis]
20 Zhu L, Zhao D, Xu L, Sun M, Song Y, Liu M, Li M, Zhang J. A Fluorescent “Turn-On” Clutch Probe for Plasma Cell-Free DNA Identification from Lung Cancer Patients. Nanomaterials 2022;12:1262. [DOI: 10.3390/nano12081262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Haldavnekar R, Venkatakrishnan A, Kiani A. Tracking the Evolution of Metastasis with Self-Functionalized 3D Nanoprobes. ACS Appl Bio Mater 2022. [PMID: 35316034 DOI: 10.1021/acsabm.2c00043] [Reference Citation Analysis]
22 Mio C, Damante G. Challenges in promoter methylation analysis in the new era of translational oncology: a focus on liquid biopsy. Biochim Biophys Acta Mol Basis Dis 2022;1868:166390. [PMID: 35296416 DOI: 10.1016/j.bbadis.2022.166390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Wang Y, Wang Y, Hui H, Fan X, Wang T, Xia W, Liu L. MicroRNA expression is deregulated by aberrant methylation in B-cell acute lymphoblastic leukemia mouse model. Mol Biol Rep 2022;49:1731-9. [PMID: 35001247 DOI: 10.1007/s11033-021-06982-x] [Reference Citation Analysis]
24 Rupp B, Ball H, Wuchu F, Nagrath D, Nagrath S. Circulating tumor cells in precision medicine: challenges and opportunities. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Chen D, Wu Y, Tilley RD, Gooding JJ. Rapid and ultrasensitive electrochemical detection of DNA methylation for ovarian cancer diagnosis. Biosens Bioelectron 2022;206:114126. [PMID: 35240438 DOI: 10.1016/j.bios.2022.114126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Pellini B, Chaudhuri AA. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. J Clin Oncol 2022;40:567-75. [PMID: 34985936 DOI: 10.1200/JCO.21.01929] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
27 Tivey A, Britton F, Scott JA, Rothwell D, Lorigan P, Lee R. Circulating Tumour DNA in Melanoma-Clinic Ready? Curr Oncol Rep 2022. [PMID: 35133615 DOI: 10.1007/s11912-021-01151-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cucchiara F, Scarpitta R, Crucitta S, Scatena C, Arici R, Naccarato AG, Fogli S, Danesi R, Del Re M. Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. Pharmacogenomics 2022;23:119-34. [PMID: 35006002 DOI: 10.2217/pgs-2021-0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tost J. Current and Emerging Technologies for the Analysis of the Genome-Wide and Locus-Specific DNA Methylation Patterns. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-031-11454-0_16] [Reference Citation Analysis]
30 Long Q, Huang C, Huang J, Meng Q, Cheng Y, Li Y, He L, Chen M, Zhang C, Wang X, Zhu W, Peng J, Shi D, Zheng F, Dong P, Deng W. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.11.016] [Reference Citation Analysis]
31 Huang J, Soupir AC, Schlick BD, Teng M, Sahin IH, Permuth JB, Siegel EM, Manley BJ, Pellini B, Wang L. Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers (Basel) 2021;13:5611. [PMID: 34830765 DOI: 10.3390/cancers13225611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Honoré N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact. Cancers (Basel) 2021;13:5364. [PMID: 34771526 DOI: 10.3390/cancers13215364] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Jiang H, Yu Q, Chen X, Zhang C, Shen J, Shen M, Yang Y, Wang B, Pan B, Guo W. Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients. J Clin Lab Anal 2021;35:e24030. [PMID: 34591323 DOI: 10.1002/jcla.24030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Loewe RP, Kirchner B, Grätz C, Bui ML, Pfaffl MW. Next Generation Tumor-Diagnostik. TD 2021;19:230-232. [DOI: 10.47184/td.2021.03.07] [Reference Citation Analysis]
35 Barefoot ME, Loyfer N, Kiliti AJ, McDeed AP 4th, Kaplan T, Wellstein A. Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA. Front Genet 2021;12:671057. [PMID: 34386036 DOI: 10.3389/fgene.2021.671057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
36 Roy D, Lucci A, Ignatiadis M, Jeffrey SS. Cell-free circulating tumor DNA profiling in cancer management. Trends Mol Med 2021:S1471-4914(21)00182-9. [PMID: 34312074 DOI: 10.1016/j.molmed.2021.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
37 Han BW, Cai GX, Liu Q, Yang X, Guo ZW, Huang LM, Li K, Ouyang GJ, Yang XX, Ye GL, Wu YS. Noninvasive discrimination of benign and malignant breast lesions using genome-wide nucleosome profiles of plasma cell-free DNA. Clin Chim Acta 2021;520:95-100. [PMID: 34107314 DOI: 10.1016/j.cca.2021.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Rapado-González Ó, López-Cedrún JL, López-López R, Rodríguez-Ces AM, Suárez-Cunqueiro MM. Saliva Gene Promoter Hypermethylation as a Biomarker in Oral Cancer. J Clin Med 2021;10:1931. [PMID: 33947071 DOI: 10.3390/jcm10091931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, Bargiacchi S, Macagno M, Grammatico P, Giannini G, Cortesi E, Di Nicolantonio F, Gazzaniga P. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Lett 2021;507:89-96. [PMID: 33744389 DOI: 10.1016/j.canlet.2021.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]